| Name | Title | Contact Details |
|---|
Phocus is a company that provides a product to fuel creativity and elevate the mind.
Germiphene Corporation is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NuLease Medical Solutions is the Drug & Alcohol Treatment center in Kentucky with a treatment program for Opioid and Alcohol use disorders.
Avecia Biotechnology is a Milford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.